Symbols

XBI

State Street SPDR S&P Biotech ETF·NYSE

--(--)

Key Stats

Assets Under Management

8.39BUSD

Fund Flows (1Y)

-339.70MUSD

Dividend Yield

0.37%

Discount/Premium to NAV

-0.07%

Shares Outstanding

67.95M

Expense Ratio

0.35%

About State Street SPDR S&P Biotech ETF

Issuer

State Street Global Advisors

Brand

SPDR

Home Page

https://www.ssga.com/us/en/intermediary/etfs/state-street-spdr-sp-biotech-etf-xbi

Inception Date

Jan 31, 2006

Structure

Open-Ended Fund

Index Tracked

S&P Biotechnology Select Industry Index

Management Style

Passive

Dividend Treatment

Distributes

Distribution Tax Treatment

Qualified dividends

Income Tax Type

Capital Gains

Max ST Capital Gains Rate

39.60%

Max LT Capital Gains Rate

20.00%

Primary Advisor

SSgA Funds Management, Inc.

Distributor

State Street Corp. (Fund Distributor)

XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.